nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—ABCB1—Mitomycin—urinary bladder cancer	0.0687	0.114	CbGbCtD
Buprenorphine—CYP2A6—Fluorouracil—urinary bladder cancer	0.0507	0.0843	CbGbCtD
Buprenorphine—ABCG2—Fluorouracil—urinary bladder cancer	0.0469	0.078	CbGbCtD
Buprenorphine—ABCG2—Carboplatin—urinary bladder cancer	0.0466	0.0775	CbGbCtD
Buprenorphine—ABCG2—Cisplatin—urinary bladder cancer	0.0398	0.0663	CbGbCtD
Buprenorphine—ABCG2—Etoposide—urinary bladder cancer	0.0391	0.0651	CbGbCtD
Buprenorphine—CYP3A4—Thiotepa—urinary bladder cancer	0.0312	0.0519	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—urinary bladder cancer	0.0267	0.0444	CbGbCtD
Buprenorphine—ABCG2—Methotrexate—urinary bladder cancer	0.0259	0.043	CbGbCtD
Buprenorphine—CYP2C8—Fluorouracil—urinary bladder cancer	0.025	0.0415	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—urinary bladder cancer	0.0217	0.0361	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—urinary bladder cancer	0.0208	0.0347	CbGbCtD
Buprenorphine—ABCB1—Gemcitabine—urinary bladder cancer	0.0198	0.0329	CbGbCtD
Buprenorphine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0193	0.0322	CbGbCtD
Buprenorphine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0174	0.029	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—urinary bladder cancer	0.0161	0.0268	CbGbCtD
Buprenorphine—CYP2C9—Cisplatin—urinary bladder cancer	0.0148	0.0246	CbGbCtD
Buprenorphine—ABCB1—Cisplatin—urinary bladder cancer	0.0144	0.0239	CbGbCtD
Buprenorphine—ABCB1—Etoposide—urinary bladder cancer	0.0141	0.0235	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—urinary bladder cancer	0.00963	0.016	CbGbCtD
Buprenorphine—ABCB1—Methotrexate—urinary bladder cancer	0.00932	0.0155	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00907	0.0151	CbGbCtD
Buprenorphine—CYP3A4—Etoposide—urinary bladder cancer	0.00846	0.0141	CbGbCtD
Buprenorphine—CYP3A4—Doxorubicin—urinary bladder cancer	0.00577	0.00959	CbGbCtD
Buprenorphine—CYP2C19—urine—urinary bladder cancer	0.00367	0.0764	CbGeAlD
Buprenorphine—CYP1A2—urine—urinary bladder cancer	0.003	0.0624	CbGeAlD
Buprenorphine—OPRL1—female reproductive system—urinary bladder cancer	0.00297	0.0618	CbGeAlD
Buprenorphine—CYP2C9—urine—urinary bladder cancer	0.00285	0.0592	CbGeAlD
Buprenorphine—OPRK1—prostate gland—urinary bladder cancer	0.00269	0.0559	CbGeAlD
Buprenorphine—UGT1A9—renal system—urinary bladder cancer	0.00242	0.0503	CbGeAlD
Buprenorphine—CYP3A4—urine—urinary bladder cancer	0.00217	0.0452	CbGeAlD
Buprenorphine—CYP2D6—urine—urinary bladder cancer	0.00214	0.0444	CbGeAlD
Buprenorphine—CYP2A6—prostate gland—urinary bladder cancer	0.00205	0.0426	CbGeAlD
Buprenorphine—OPRD1—renal system—urinary bladder cancer	0.00191	0.0398	CbGeAlD
Buprenorphine—OPRL1—lymph node—urinary bladder cancer	0.00174	0.0362	CbGeAlD
Buprenorphine—CYP2A6—seminal vesicle—urinary bladder cancer	0.00173	0.0361	CbGeAlD
Buprenorphine—CYP2C18—vagina—urinary bladder cancer	0.00153	0.0319	CbGeAlD
Buprenorphine—OPRK1—female reproductive system—urinary bladder cancer	0.00147	0.0305	CbGeAlD
Buprenorphine—ABCG2—prostate gland—urinary bladder cancer	0.00112	0.0233	CbGeAlD
Buprenorphine—CYP3A5—prostate gland—urinary bladder cancer	0.00104	0.0216	CbGeAlD
Buprenorphine—CYP2A6—vagina—urinary bladder cancer	0.00101	0.021	CbGeAlD
Buprenorphine—ABCG2—seminal vesicle—urinary bladder cancer	0.000947	0.0197	CbGeAlD
Buprenorphine—CYP2C8—renal system—urinary bladder cancer	0.000785	0.0163	CbGeAlD
Buprenorphine—ABCG2—urethra—urinary bladder cancer	0.000749	0.0156	CbGeAlD
Buprenorphine—CYP1A2—renal system—urinary bladder cancer	0.000734	0.0153	CbGeAlD
Buprenorphine—CYP3A5—renal system—urinary bladder cancer	0.000708	0.0147	CbGeAlD
Buprenorphine—CYP2C19—vagina—urinary bladder cancer	0.000651	0.0135	CbGeAlD
Buprenorphine—CYP2C8—female reproductive system—urinary bladder cancer	0.000628	0.0131	CbGeAlD
Buprenorphine—CYP2C8—vagina—urinary bladder cancer	0.000568	0.0118	CbGeAlD
Buprenorphine—CYP2C9—female reproductive system—urinary bladder cancer	0.000558	0.0116	CbGeAlD
Buprenorphine—ABCG2—vagina—urinary bladder cancer	0.000553	0.0115	CbGeAlD
Buprenorphine—ABCB1—prostate gland—urinary bladder cancer	0.000552	0.0115	CbGeAlD
Buprenorphine—CYP3A4—renal system—urinary bladder cancer	0.000532	0.0111	CbGeAlD
Buprenorphine—CYP2D6—renal system—urinary bladder cancer	0.000523	0.0109	CbGeAlD
Buprenorphine—CYP3A5—vagina—urinary bladder cancer	0.000513	0.0107	CbGeAlD
Buprenorphine—ABCB1—seminal vesicle—urinary bladder cancer	0.000467	0.00971	CbGeAlD
Buprenorphine—CYP3A4—female reproductive system—urinary bladder cancer	0.000426	0.00885	CbGeAlD
Buprenorphine—CYP2D6—female reproductive system—urinary bladder cancer	0.000419	0.00871	CbGeAlD
Buprenorphine—ABCB1—epithelium—urinary bladder cancer	0.000406	0.00843	CbGeAlD
Buprenorphine—ABCB1—renal system—urinary bladder cancer	0.000376	0.00782	CbGeAlD
Buprenorphine—ABCB1—urethra—urinary bladder cancer	0.00037	0.00768	CbGeAlD
Buprenorphine—ABCG2—lymph node—urinary bladder cancer	0.000357	0.00743	CbGeAlD
Buprenorphine—Naloxone—ESR1—urinary bladder cancer	0.000314	1	CrCbGaD
Buprenorphine—ABCB1—female reproductive system—urinary bladder cancer	0.000301	0.00626	CbGeAlD
Buprenorphine—ABCB1—vagina—urinary bladder cancer	0.000273	0.00567	CbGeAlD
Buprenorphine—ABCB1—lymph node—urinary bladder cancer	0.000176	0.00366	CbGeAlD
Buprenorphine—Body temperature increased—Etoposide—urinary bladder cancer	0.000154	0.000729	CcSEcCtD
Buprenorphine—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000154	0.000729	CcSEcCtD
Buprenorphine—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000154	0.000729	CcSEcCtD
Buprenorphine—Eye disorder—Methotrexate—urinary bladder cancer	0.000153	0.000726	CcSEcCtD
Buprenorphine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000153	0.000726	CcSEcCtD
Buprenorphine—Tinnitus—Methotrexate—urinary bladder cancer	0.000153	0.000725	CcSEcCtD
Buprenorphine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000152	0.000724	CcSEcCtD
Buprenorphine—Asthenia—Cisplatin—urinary bladder cancer	0.000152	0.000722	CcSEcCtD
Buprenorphine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000152	0.000722	CcSEcCtD
Buprenorphine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000152	0.000721	CcSEcCtD
Buprenorphine—Sweating—Doxorubicin—urinary bladder cancer	0.000151	0.000719	CcSEcCtD
Buprenorphine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000151	0.000718	CcSEcCtD
Buprenorphine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000151	0.000717	CcSEcCtD
Buprenorphine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000151	0.000715	CcSEcCtD
Buprenorphine—Urethral disorder—Epirubicin—urinary bladder cancer	0.00015	0.000713	CcSEcCtD
Buprenorphine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000149	0.000709	CcSEcCtD
Buprenorphine—Angiopathy—Methotrexate—urinary bladder cancer	0.000149	0.000705	CcSEcCtD
Buprenorphine—Sinusitis—Doxorubicin—urinary bladder cancer	0.000148	0.000703	CcSEcCtD
Buprenorphine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000148	0.000702	CcSEcCtD
Buprenorphine—Dizziness—Fluorouracil—urinary bladder cancer	0.000148	0.000702	CcSEcCtD
Buprenorphine—Visual impairment—Epirubicin—urinary bladder cancer	0.000148	0.000701	CcSEcCtD
Buprenorphine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000148	0.000701	CcSEcCtD
Buprenorphine—Chills—Methotrexate—urinary bladder cancer	0.000147	0.000698	CcSEcCtD
Buprenorphine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000145	0.000689	CcSEcCtD
Buprenorphine—Vomiting—Gemcitabine—urinary bladder cancer	0.000145	0.000687	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000144	0.000685	CcSEcCtD
Buprenorphine—Mental disorder—Methotrexate—urinary bladder cancer	0.000143	0.000681	CcSEcCtD
Buprenorphine—Rash—Gemcitabine—urinary bladder cancer	0.000143	0.000681	CcSEcCtD
Buprenorphine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000143	0.00068	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—urinary bladder cancer	0.000143	0.00068	CcSEcCtD
Buprenorphine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000143	0.000679	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—urinary bladder cancer	0.000143	0.000678	CcSEcCtD
Buprenorphine—Erythema—Methotrexate—urinary bladder cancer	0.000143	0.000677	CcSEcCtD
Buprenorphine—Malnutrition—Methotrexate—urinary bladder cancer	0.000143	0.000677	CcSEcCtD
Buprenorphine—Headache—Gemcitabine—urinary bladder cancer	0.000142	0.000676	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—urinary bladder cancer	0.000142	0.000675	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000142	0.000675	CcSEcCtD
Buprenorphine—Vomiting—Fluorouracil—urinary bladder cancer	0.000142	0.000675	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—urinary bladder cancer	0.000142	0.000675	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000141	0.00067	CcSEcCtD
Buprenorphine—Rash—Fluorouracil—urinary bladder cancer	0.000141	0.000669	CcSEcCtD
Buprenorphine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000141	0.000669	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000141	0.000668	CcSEcCtD
Buprenorphine—Headache—Fluorouracil—urinary bladder cancer	0.00014	0.000665	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.00014	0.000665	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00014	0.000663	CcSEcCtD
Buprenorphine—Dysgeusia—Methotrexate—urinary bladder cancer	0.00014	0.000663	CcSEcCtD
Buprenorphine—Asthenia—Etoposide—urinary bladder cancer	0.000139	0.000662	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000139	0.000661	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—urinary bladder cancer	0.000139	0.00066	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000139	0.00066	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000138	0.000657	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000138	0.000656	CcSEcCtD
Buprenorphine—Back pain—Methotrexate—urinary bladder cancer	0.000138	0.000655	CcSEcCtD
Buprenorphine—Chills—Epirubicin—urinary bladder cancer	0.000137	0.000653	CcSEcCtD
Buprenorphine—Pruritus—Etoposide—urinary bladder cancer	0.000137	0.000652	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000137	0.000649	CcSEcCtD
Buprenorphine—Nausea—Gemcitabine—urinary bladder cancer	0.000135	0.000641	CcSEcCtD
Buprenorphine—Vomiting—Cisplatin—urinary bladder cancer	0.000135	0.00064	CcSEcCtD
Buprenorphine—Vision blurred—Methotrexate—urinary bladder cancer	0.000134	0.000638	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—urinary bladder cancer	0.000134	0.000637	CcSEcCtD
Buprenorphine—Rash—Cisplatin—urinary bladder cancer	0.000134	0.000635	CcSEcCtD
Buprenorphine—Dermatitis—Cisplatin—urinary bladder cancer	0.000134	0.000634	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—urinary bladder cancer	0.000133	0.000633	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—urinary bladder cancer	0.000133	0.000633	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—urinary bladder cancer	0.000133	0.000631	CcSEcCtD
Buprenorphine—Nausea—Fluorouracil—urinary bladder cancer	0.000133	0.000631	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000132	0.000629	CcSEcCtD
Buprenorphine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000132	0.000628	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000132	0.000628	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000132	0.000625	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—urinary bladder cancer	0.000132	0.000625	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—urinary bladder cancer	0.000131	0.000624	CcSEcCtD
Buprenorphine—Tension—Epirubicin—urinary bladder cancer	0.000131	0.000621	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000131	0.00062	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—urinary bladder cancer	0.00013	0.000615	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—urinary bladder cancer	0.000129	0.000613	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000129	0.000611	CcSEcCtD
Buprenorphine—Malaise—Methotrexate—urinary bladder cancer	0.000129	0.00061	CcSEcCtD
Buprenorphine—Dizziness—Etoposide—urinary bladder cancer	0.000128	0.00061	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000128	0.000609	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000128	0.000608	CcSEcCtD
Buprenorphine—Vertigo—Methotrexate—urinary bladder cancer	0.000128	0.000608	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000128	0.000607	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—urinary bladder cancer	0.000127	0.000604	CcSEcCtD
Buprenorphine—Nausea—Cisplatin—urinary bladder cancer	0.000126	0.000598	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—urinary bladder cancer	0.000126	0.000597	CcSEcCtD
Buprenorphine—Cough—Methotrexate—urinary bladder cancer	0.000124	0.000591	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000124	0.00059	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000124	0.000588	CcSEcCtD
Buprenorphine—Convulsion—Methotrexate—urinary bladder cancer	0.000123	0.000586	CcSEcCtD
Buprenorphine—Vomiting—Etoposide—urinary bladder cancer	0.000123	0.000586	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000123	0.000586	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—urinary bladder cancer	0.000123	0.000586	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—urinary bladder cancer	0.000123	0.000582	CcSEcCtD
Buprenorphine—Rash—Etoposide—urinary bladder cancer	0.000122	0.000581	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—urinary bladder cancer	0.000122	0.000581	CcSEcCtD
Buprenorphine—Headache—Etoposide—urinary bladder cancer	0.000122	0.000578	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—urinary bladder cancer	0.000122	0.000577	CcSEcCtD
Buprenorphine—Arthralgia—Methotrexate—urinary bladder cancer	0.000121	0.000576	CcSEcCtD
Buprenorphine—Myalgia—Methotrexate—urinary bladder cancer	0.000121	0.000576	CcSEcCtD
Buprenorphine—Chest pain—Methotrexate—urinary bladder cancer	0.000121	0.000576	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—urinary bladder cancer	0.000121	0.000575	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000121	0.000574	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000121	0.000572	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—urinary bladder cancer	0.00012	0.000571	CcSEcCtD
Buprenorphine—Discomfort—Methotrexate—urinary bladder cancer	0.00012	0.000569	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—urinary bladder cancer	0.00012	0.000569	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—urinary bladder cancer	0.00012	0.000569	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—urinary bladder cancer	0.00012	0.000568	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—urinary bladder cancer	0.000119	0.000567	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000119	0.000563	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—urinary bladder cancer	0.000118	0.00056	CcSEcCtD
Buprenorphine—Confusional state—Methotrexate—urinary bladder cancer	0.000117	0.000557	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000117	0.000557	CcSEcCtD
Buprenorphine—Cough—Epirubicin—urinary bladder cancer	0.000116	0.000553	CcSEcCtD
Buprenorphine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000116	0.000552	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000116	0.000552	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—urinary bladder cancer	0.000116	0.000549	CcSEcCtD
Buprenorphine—Infection—Methotrexate—urinary bladder cancer	0.000116	0.000549	CcSEcCtD
Buprenorphine—Nausea—Etoposide—urinary bladder cancer	0.000115	0.000548	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—urinary bladder cancer	0.000115	0.000547	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000115	0.000544	CcSEcCtD
Buprenorphine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000114	0.000542	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—urinary bladder cancer	0.000114	0.000539	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—urinary bladder cancer	0.000114	0.000539	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—urinary bladder cancer	0.000114	0.000539	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—urinary bladder cancer	0.000113	0.000538	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—urinary bladder cancer	0.000113	0.000537	CcSEcCtD
Buprenorphine—Skin disorder—Methotrexate—urinary bladder cancer	0.000113	0.000536	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000113	0.000535	CcSEcCtD
Buprenorphine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000112	0.000534	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—urinary bladder cancer	0.000112	0.000533	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—urinary bladder cancer	0.000111	0.000528	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—urinary bladder cancer	0.000111	0.000527	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—urinary bladder cancer	0.000111	0.000526	CcSEcCtD
Buprenorphine—Anorexia—Methotrexate—urinary bladder cancer	0.000111	0.000526	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—urinary bladder cancer	0.000111	0.000525	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—urinary bladder cancer	0.00011	0.000521	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—urinary bladder cancer	0.000109	0.000518	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—urinary bladder cancer	0.000109	0.000517	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000109	0.000517	CcSEcCtD
Buprenorphine—Hypotension—Methotrexate—urinary bladder cancer	0.000109	0.000516	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000108	0.000515	CcSEcCtD
Buprenorphine—Infection—Epirubicin—urinary bladder cancer	0.000108	0.000513	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—urinary bladder cancer	0.000108	0.000511	CcSEcCtD
Buprenorphine—Shock—Epirubicin—urinary bladder cancer	0.000107	0.000508	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—urinary bladder cancer	0.000107	0.000508	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000107	0.000507	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—urinary bladder cancer	0.000107	0.000506	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—urinary bladder cancer	0.000106	0.000504	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000106	0.000503	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—urinary bladder cancer	0.000106	0.000502	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000105	0.0005	CcSEcCtD
Buprenorphine—Insomnia—Methotrexate—urinary bladder cancer	0.000105	0.0005	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000105	0.000499	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—urinary bladder cancer	0.000105	0.000499	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—urinary bladder cancer	0.000105	0.000499	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—urinary bladder cancer	0.000105	0.000497	CcSEcCtD
Buprenorphine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000104	0.000496	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000104	0.000495	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—urinary bladder cancer	0.000104	0.000493	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—urinary bladder cancer	0.000104	0.000493	CcSEcCtD
Buprenorphine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000104	0.000492	CcSEcCtD
Buprenorphine—Somnolence—Methotrexate—urinary bladder cancer	0.000103	0.000491	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000103	0.000488	CcSEcCtD
Buprenorphine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000102	0.000486	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—urinary bladder cancer	0.000102	0.000483	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—urinary bladder cancer	0.000102	0.000482	CcSEcCtD
Buprenorphine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000101	0.00048	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—urinary bladder cancer	0.000101	0.000478	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000101	0.000478	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.0001	0.000477	CcSEcCtD
Buprenorphine—Fatigue—Methotrexate—urinary bladder cancer	0.0001	0.000476	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—urinary bladder cancer	0.0001	0.000475	CcSEcCtD
Buprenorphine—Pain—Methotrexate—urinary bladder cancer	9.95e-05	0.000472	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.92e-05	0.000471	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—urinary bladder cancer	9.91e-05	0.00047	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.88e-05	0.000469	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—urinary bladder cancer	9.85e-05	0.000467	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—urinary bladder cancer	9.83e-05	0.000467	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—urinary bladder cancer	9.78e-05	0.000465	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—urinary bladder cancer	9.77e-05	0.000464	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.74e-05	0.000462	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—urinary bladder cancer	9.71e-05	0.000461	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—urinary bladder cancer	9.68e-05	0.000459	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—urinary bladder cancer	9.6e-05	0.000456	CcSEcCtD
Buprenorphine—Feeling abnormal—Methotrexate—urinary bladder cancer	9.59e-05	0.000455	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—urinary bladder cancer	9.58e-05	0.000455	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.51e-05	0.000452	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—urinary bladder cancer	9.46e-05	0.000449	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—urinary bladder cancer	9.41e-05	0.000447	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	9.4e-05	0.000446	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—urinary bladder cancer	9.39e-05	0.000446	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—urinary bladder cancer	9.31e-05	0.000442	CcSEcCtD
Buprenorphine—Pain—Epirubicin—urinary bladder cancer	9.31e-05	0.000442	CcSEcCtD
Buprenorphine—Urticaria—Methotrexate—urinary bladder cancer	9.24e-05	0.000439	CcSEcCtD
Buprenorphine—Abdominal pain—Methotrexate—urinary bladder cancer	9.2e-05	0.000437	CcSEcCtD
Buprenorphine—Body temperature increased—Methotrexate—urinary bladder cancer	9.2e-05	0.000437	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	9.18e-05	0.000436	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—urinary bladder cancer	9.11e-05	0.000433	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—urinary bladder cancer	9.04e-05	0.000429	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—urinary bladder cancer	8.98e-05	0.000426	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—urinary bladder cancer	8.97e-05	0.000426	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—urinary bladder cancer	8.95e-05	0.000425	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.9e-05	0.000423	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—urinary bladder cancer	8.87e-05	0.000421	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—urinary bladder cancer	8.76e-05	0.000416	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.7e-05	0.000413	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—urinary bladder cancer	8.68e-05	0.000412	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—urinary bladder cancer	8.65e-05	0.000411	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—urinary bladder cancer	8.61e-05	0.000409	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—urinary bladder cancer	8.61e-05	0.000409	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—urinary bladder cancer	8.61e-05	0.000409	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—urinary bladder cancer	8.61e-05	0.000409	CcSEcCtD
Buprenorphine—Hypersensitivity—Methotrexate—urinary bladder cancer	8.57e-05	0.000407	CcSEcCtD
Buprenorphine—Asthenia—Methotrexate—urinary bladder cancer	8.35e-05	0.000396	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.3e-05	0.000394	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	8.24e-05	0.000391	CcSEcCtD
Buprenorphine—Pruritus—Methotrexate—urinary bladder cancer	8.23e-05	0.000391	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—urinary bladder cancer	8.02e-05	0.000381	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—urinary bladder cancer	8e-05	0.00038	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—urinary bladder cancer	7.96e-05	0.000378	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—urinary bladder cancer	7.96e-05	0.000378	CcSEcCtD
Buprenorphine—Diarrhoea—Methotrexate—urinary bladder cancer	7.96e-05	0.000378	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—urinary bladder cancer	7.81e-05	0.000371	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—urinary bladder cancer	7.7e-05	0.000366	CcSEcCtD
Buprenorphine—Dizziness—Methotrexate—urinary bladder cancer	7.69e-05	0.000365	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—urinary bladder cancer	7.45e-05	0.000354	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.42e-05	0.000352	CcSEcCtD
Buprenorphine—Vomiting—Methotrexate—urinary bladder cancer	7.4e-05	0.000351	CcSEcCtD
Buprenorphine—Rash—Methotrexate—urinary bladder cancer	7.33e-05	0.000348	CcSEcCtD
Buprenorphine—Dermatitis—Methotrexate—urinary bladder cancer	7.33e-05	0.000348	CcSEcCtD
Buprenorphine—Headache—Methotrexate—urinary bladder cancer	7.29e-05	0.000346	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—urinary bladder cancer	7.23e-05	0.000343	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—urinary bladder cancer	7.2e-05	0.000342	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—urinary bladder cancer	7.13e-05	0.000338	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—urinary bladder cancer	6.92e-05	0.000329	CcSEcCtD
Buprenorphine—Nausea—Methotrexate—urinary bladder cancer	6.91e-05	0.000328	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—urinary bladder cancer	6.89e-05	0.000327	CcSEcCtD
Buprenorphine—Rash—Epirubicin—urinary bladder cancer	6.86e-05	0.000326	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—urinary bladder cancer	6.86e-05	0.000326	CcSEcCtD
Buprenorphine—Headache—Epirubicin—urinary bladder cancer	6.82e-05	0.000324	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—urinary bladder cancer	6.66e-05	0.000316	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—urinary bladder cancer	6.47e-05	0.000307	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—urinary bladder cancer	6.4e-05	0.000304	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—urinary bladder cancer	6.35e-05	0.000302	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—urinary bladder cancer	6.35e-05	0.000301	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—urinary bladder cancer	6.31e-05	0.0003	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—urinary bladder cancer	5.98e-05	0.000284	CcSEcCtD
Buprenorphine—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.58e-05	0.000113	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.57e-05	0.000113	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.57e-05	0.000112	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.57e-05	0.000112	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.56e-05	0.000112	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—FGFR3—urinary bladder cancer	1.55e-05	0.000111	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—TYMS—urinary bladder cancer	1.55e-05	0.000111	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	1.53e-05	0.00011	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	1.53e-05	0.00011	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ENO2—urinary bladder cancer	1.51e-05	0.000108	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	1.51e-05	0.000108	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ESR1—urinary bladder cancer	1.51e-05	0.000108	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CREBBP—urinary bladder cancer	1.51e-05	0.000108	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.5e-05	0.000108	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.5e-05	0.000107	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.5e-05	0.000107	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IGF1—urinary bladder cancer	1.49e-05	0.000107	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—MTHFR—urinary bladder cancer	1.49e-05	0.000107	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.49e-05	0.000106	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—EGFR—urinary bladder cancer	1.48e-05	0.000106	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.48e-05	0.000106	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.47e-05	0.000106	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.47e-05	0.000106	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.47e-05	0.000105	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—GPX1—urinary bladder cancer	1.47e-05	0.000105	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.46e-05	0.000105	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.44e-05	0.000103	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	1.44e-05	0.000103	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.44e-05	0.000103	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	1.43e-05	0.000102	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.43e-05	0.000102	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PPARG—urinary bladder cancer	1.42e-05	0.000102	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	1.42e-05	0.000101	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—KRAS—urinary bladder cancer	1.4e-05	0.0001	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.39e-05	9.94e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.39e-05	9.94e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.38e-05	9.86e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.38e-05	9.86e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.37e-05	9.8e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	1.37e-05	9.78e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—RHOA—urinary bladder cancer	1.36e-05	9.76e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.36e-05	9.76e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	1.35e-05	9.68e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.35e-05	9.64e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.34e-05	9.58e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.34e-05	9.56e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.32e-05	9.47e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	1.32e-05	9.46e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.32e-05	9.41e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.31e-05	9.4e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	1.31e-05	9.4e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	1.31e-05	9.35e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	1.3e-05	9.3e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	1.28e-05	9.13e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.27e-05	9.09e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—ERBB2—urinary bladder cancer	1.26e-05	9.04e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.26e-05	8.99e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PTEN—urinary bladder cancer	1.23e-05	8.84e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	1.23e-05	8.78e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.22e-05	8.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.22e-05	8.71e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.21e-05	8.64e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.21e-05	8.64e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.21e-05	8.64e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CXCL8—urinary bladder cancer	1.2e-05	8.57e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.2e-05	8.56e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	1.2e-05	8.56e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling by GPCR—HRAS—urinary bladder cancer	1.19e-05	8.52e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.19e-05	8.5e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.18e-05	8.45e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—EP300—urinary bladder cancer	1.18e-05	8.43e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.18e-05	8.42e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.18e-05	8.42e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.17e-05	8.37e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.16e-05	8.3e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.16e-05	8.27e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.15e-05	8.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.15e-05	8.23e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL2—urinary bladder cancer	1.14e-05	8.19e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.14e-05	8.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.14e-05	8.14e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.14e-05	8.13e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.13e-05	8.12e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.12e-05	8.04e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.12e-05	8.01e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	1.12e-05	8.01e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	1.12e-05	8e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CCND1—urinary bladder cancer	1.12e-05	7.99e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.11e-05	7.94e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	1.11e-05	7.93e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	1.1e-05	7.9e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.1e-05	7.88e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	1.1e-05	7.86e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PPARG—urinary bladder cancer	1.1e-05	7.85e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MMP9—urinary bladder cancer	1.08e-05	7.75e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.08e-05	7.72e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.08e-05	7.71e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PTEN—urinary bladder cancer	1.08e-05	7.71e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.07e-05	7.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.06e-05	7.57e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	1.05e-05	7.54e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	1.05e-05	7.52e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.05e-05	7.48e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.05e-05	7.48e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	1.04e-05	7.47e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	1.04e-05	7.42e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.03e-05	7.37e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EP300—urinary bladder cancer	1.03e-05	7.35e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.02e-05	7.27e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	1.01e-05	7.24e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	1e-05	7.18e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1e-05	7.16e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—SRC—urinary bladder cancer	9.99e-06	7.15e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	9.91e-06	7.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	9.83e-06	7.03e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.82e-06	7.03e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	9.81e-06	7.02e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	9.78e-06	7e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PTEN—urinary bladder cancer	9.76e-06	6.99e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	9.5e-06	6.8e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTGS2—urinary bladder cancer	9.5e-06	6.8e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	9.49e-06	6.79e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.46e-06	6.77e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	9.44e-06	6.76e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—TYMS—urinary bladder cancer	9.44e-06	6.76e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	9.41e-06	6.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.39e-06	6.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	9.36e-06	6.7e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	9.34e-06	6.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	9.33e-06	6.68e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	9.33e-06	6.68e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—urinary bladder cancer	9.31e-06	6.66e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	9.26e-06	6.63e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	9.24e-06	6.61e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—urinary bladder cancer	9.21e-06	6.59e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.2e-06	6.59e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.11e-06	6.52e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.11e-06	6.52e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	9.08e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	9.08e-06	6.5e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	9.01e-06	6.45e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.96e-06	6.41e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	8.95e-06	6.41e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	8.94e-06	6.39e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	8.88e-06	6.35e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	8.82e-06	6.31e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	8.81e-06	6.3e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	8.77e-06	6.28e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	8.76e-06	6.27e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	8.75e-06	6.26e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GPX1—urinary bladder cancer	8.72e-06	6.24e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	8.68e-06	6.21e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PPARG—urinary bladder cancer	8.65e-06	6.19e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	8.63e-06	6.17e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	8.61e-06	6.16e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	8.58e-06	6.14e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	8.58e-06	6.14e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	8.56e-06	6.13e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	8.51e-06	6.09e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	8.51e-06	6.09e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	8.48e-06	6.07e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	8.31e-06	5.95e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—urinary bladder cancer	8.28e-06	5.93e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	8.27e-06	5.92e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	8.27e-06	5.92e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	8.25e-06	5.9e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.22e-06	5.88e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—urinary bladder cancer	8.21e-06	5.87e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	8.15e-06	5.83e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.07e-06	5.77e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.05e-06	5.76e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	8.03e-06	5.75e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.03e-06	5.74e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	8e-06	5.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	8e-06	5.72e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	7.98e-06	5.71e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	7.91e-06	5.66e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—urinary bladder cancer	7.9e-06	5.65e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	7.85e-06	5.62e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—urinary bladder cancer	7.83e-06	5.6e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	7.68e-06	5.49e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.65e-06	5.48e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	7.61e-06	5.45e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.58e-06	5.43e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—urinary bladder cancer	7.52e-06	5.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	7.52e-06	5.38e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	7.49e-06	5.36e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	7.4e-06	5.3e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.35e-06	5.26e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	7.35e-06	5.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	7.32e-06	5.24e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.27e-06	5.2e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.27e-06	5.2e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	7.25e-06	5.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	7.2e-06	5.15e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—urinary bladder cancer	7.18e-06	5.14e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	7.03e-06	5.03e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	6.96e-06	4.98e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.84e-06	4.89e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	6.8e-06	4.87e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	6.69e-06	4.79e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	6.63e-06	4.75e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.53e-06	4.67e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	6.49e-06	4.64e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	6.44e-06	4.61e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.43e-06	4.6e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	6.42e-06	4.6e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.27e-06	4.49e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	6.16e-06	4.41e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.15e-06	4.4e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	6.13e-06	4.39e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	6.11e-06	4.37e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	6.1e-06	4.36e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—urinary bladder cancer	5.93e-06	4.25e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.91e-06	4.23e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	5.89e-06	4.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	5.86e-06	4.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	5.68e-06	4.06e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—urinary bladder cancer	5.66e-06	4.05e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	5.61e-06	4.02e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	5.61e-06	4.02e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	5.45e-06	3.9e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	5.37e-06	3.85e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	5.28e-06	3.78e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	5.26e-06	3.76e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.21e-06	3.73e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	5.21e-06	3.73e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	5.14e-06	3.68e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.13e-06	3.67e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	5.01e-06	3.58e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	4.96e-06	3.55e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—urinary bladder cancer	4.9e-06	3.51e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.84e-06	3.46e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	4.8e-06	3.43e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	4.59e-06	3.28e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.48e-06	3.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—urinary bladder cancer	4.37e-06	3.13e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.27e-06	3.06e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.22e-06	3.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	4.18e-06	2.99e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	4.1e-06	2.93e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.02e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	4.02e-06	2.88e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—urinary bladder cancer	3.99e-06	2.85e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	3.86e-06	2.76e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.57e-06	2.56e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.41e-06	2.44e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	3.16e-06	2.26e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.76e-06	1.97e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—urinary bladder cancer	2.63e-06	1.88e-05	CbGpPWpGaD
